Retrospective cohort analysis shows varied outcomes for high-risk and very high-risk bladder cancer patients treated with BCG, suggesting reevaluation of EAU risk stratification.
Key Points
The study found that 5-year recurrence-free survival was significantly lower in very high-risk patients at 56%.
While adverse features were more prevalent in the very high-risk group, overall progression rates were similar at 10.4% and 9%.
The analysis involved a cohort of 211 patients treated with BCG therapy over nine years, assessing recurrence and progression outcomes.
These results imply that BCG therapy is still effective in very high-risk patients, questioning the current EAU risk assessment.